Physician profile
Kenneth A Mankowski
NPI 1942261243
$1,406,406.41
in general payments reported to CMS, 2019-2025
38 companies · $132K in 2025
The $132K reported for 2025 was more than what 99% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $276K · 2020: $125K · 2021: $179K · 2022: $188K · 2023: $316K · 2024: $191K · 2025: $132K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $481K · Travel and Lodging: $94K · Consulting Fee: $47K · Food and Beverage: $16K · Education: $17.77.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $480,714.67 |
| Travel and Lodging | $94,433.05 |
| Consulting Fee | $47,249.00 |
| Food and Beverage | $16,056.82 |
| Education | $17.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $562,391.61 | 2019-2025 | Vumerity, Tysabri, Tysabri |
| Emd Serono, INC. | $414,504.14 | 2019-2025 | Mavenclad, Mavenclad |
| Tg Therapeutics, INC. | $207,400.65 | 2021-2025 | Briumvi |
| Genzyme Corporation | $108,241.85 | 2019-2025 | |
| Genentech USA, INC. | $50,704.43 | 2019-2024 | Ocrevus |
| Amgen INC. | $16,491.90 | 2021-2025 | Uplizna |
| Horizon Therapeutics Plc | $14,650.85 | 2021-2023 | Uplizna |
| Novartis Pharmaceuticals Corporation | $7,419.23 | 2019-2022 | |
| Cardinal Health 110 LLC | $6,805.97 | 2023-2024 | |
| Sandoz INC. | $5,875.00 | 2023 | |
| Banner Life Sciences, LLC | $5,310.00 | 2022 | |
| Ares Trading Sa | $2,780.00 | 2024 | |
| Celgene Corporation | $2,481.36 | 2020-2023 | Zeposia |
| Genentech, INC. | $305.30 | 2019-2020 | |
| Abbvie INC. | $178.63 | 2019-2023 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $103.12 | 2025 | Kisunla |
| Procept Biorobotics Corporation | $102.50 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $102.00 | 2024 | Acthar |
| Sanofi-Aventis U.S. LLC | $91.42 | 2020 | |
| Cardinal Health INC | $90.89 | 2025 | |
| Acorda Therapeutics, INC | $50.46 | 2019-2021 | |
| Acadia Pharmaceuticals INC | $47.65 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $45.72 | 2025 | Purified Cortrophin Gel |
| Mallinckrodt Enterprises LLC | $23.50 | 2019 | |
| Akcea Therapeutics, INC. | $21.90 | 2019 | |
| Alnylam Pharmaceuticals INC. | $21.02 | 2021 | |
| Greenwich Biosciences, INC. | $20.57 | 2021 | |
| Sk Life Science, INC. | $20.05 | 2021 | |
| Mdd US Operations, LLC | $18.54 | 2020 | |
| Kyowa Kirin, INC. | $16.48 | 2021 | |
| Tanabe Pharma America, INC. | $16.04 | 2019 | |
| Jazz Pharmaceuticals INC. | $14.44 | 2020 | |
| Avanir Pharmaceuticals, INC. | $12.99 | 2019 | |
| Vertical Pharmaceuticals, LLC | $11.82 | 2019 | |
| Zyla Life Sciences, INC. | $11.59 | 2019 | |
| Alexion Pharmaceuticals, INC. | $11.51 | 2021 | |
| Adamas Pharmaceuticals, INC. | $11.28 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kenneth Mankowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.